Risks of Lynch syndrome cancers for MSH6 mutation carriers. - sprookjes - yvandenbroek - TriplyDB

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

http://www.wikidata.org/entity/Q30492977

about

PMS2 monoallelic mutation carriers: the known unknown Replicative DNA polymerase δ but not ε proofreads errors in Cis and in Trans DNA replication fidelity and cancer Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer.Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives Familial cancer among consecutive uterine cancer patients in Sweden.A molecular inversion probe-based next-generation sequencing panel to detect germline mutations in Chinese early-onset colorectal cancer patients.Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers.A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data Colorectal cancer: molecular features and clinical opportunities Hereditary colon cancer: lynch syndrome MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.Genetic testing for lynch syndrome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.Application of molecular diagnostics for the detection of Lynch syndrome.Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers.Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases.The inherited genetics of ovarian and endometrial cancer.Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers.Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.Functional analysis in mouse embryonic stem cells reveals wild-type activity for three MSH6 variants found in suspected Lynch syndrome patients.Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers.Advances in the study of Lynch syndrome in China Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.Lynch syndrome and cervical cancer Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.Determining the frequency of de novo germline mutations in DNA mismatch repair genes.

P2860

Q27024662-796B06DD-2A5C-4F7A-B5FF-B54A31807D98 Q28258327-CB75059C-46E9-4BFB-BEDD-A077503831D4 Q28295863-71FEAC7D-B34D-4C1B-A753-394A49CE6440 Q29417133-3673802A-EBD3-4D80-8725-A6E37BBF7271 Q30234614-2DAADB4B-1944-4D77-9A60-0AEAA043D2DB Q30275554-1FF394D0-D072-444B-A013-9EF098FBDCE9 Q30361978-06EAB501-FA85-468B-B858-F44A32B70C3A Q30501708-AA097131-92F3-4640-B10A-ECC0BC99A102 Q30502502-79CFBF1E-983F-40C2-B4A4-76EF5C29AE67 Q30558412-9805F4F8-0FF3-4BBD-BEC4-512864AC74BF Q31139897-1004E45C-9F21-4C1E-A4CF-50D996C98D50 Q33646157-AD0048A7-DC45-4073-8E11-DB8A6B7660E1 Q33648552-ADAE8D05-4CE1-48E9-BFDA-69086DD3355D Q33699887-4AD84BAE-F116-4CBC-82AB-349F1DA0CCCF Q33750026-0393F644-E11F-47E9-9217-4B4D59D25424 Q33868493-C2EA13F4-0D3A-4347-A593-33D3195B281B Q33918280-3C07E7E5-DF67-4FA1-B0E3-F79C6C952F9C Q33933576-CE0A4E8A-C713-47C9-A70A-8FE744300D96 Q33956968-8F0AC281-3169-486A-BAD8-627B20474B4E Q33996492-152DB5D3-DB9F-4503-8D4A-4B6393C4DA27 Q34081267-675346AD-B9DE-41D4-91A1-4C72E6647726 Q34088809-D55D1C19-A0B4-47BB-B11E-9EA2BC2B959B Q34289520-9D167213-299F-407D-A20B-C38D27494A25 Q34346668-569DB7D1-CB6C-4926-9FAD-1E7817CD5D61 Q34481263-C499778B-0A9D-4D46-BCFD-E97807D9D3E2 Q34756357-FF4995BC-BE05-4AAD-BC12-6A7B28B1D51E Q34775177-D98D0FD3-6FDC-4376-9A58-AAB2643EA276 Q34883523-0EB5960A-D6EE-4B6E-934D-68372A481ED4 Q34961153-DFEBCC7C-DE25-4B6A-87F7-065BCC111A78 Q34990339-C06ABD43-A773-403E-A844-24BE1EA8EFA0 Q35212716-4D1082C0-26D7-43AD-AAB5-7FD05DCBE46C Q35716138-94C78C30-D5E1-4738-ACBF-82031CE31FF6 Q35799369-00A8B0DE-1D54-4C91-BDA4-2D87EF4B738F Q35925149-18CE7E91-84E0-4CE0-9337-F1F638D145C6 Q35971538-DDAACBF0-F3AB-46A9-BFD9-94C6D7752EA3 Q36051960-CED2C52D-CEE5-4F29-A7B0-7B2A8B94A246 Q36068742-0CF923A4-21E7-4FF4-9B04-528476FD1DCE Q36082471-757501B1-E215-42B9-87A3-A851D6B832DB Q36101775-BCCAAA50-024D-41E0-B84F-50789CD73B7A Q36217478-71B56695-BA90-496D-BB95-B23145CAD620

P2860

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

http://www.wikidata.org/entity/Q30492977

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@ast

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@en

type

label

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@ast

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@en

prefLabel

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@ast

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@en

P1433

Q30492977-9D8861B6-212D-4219-86EE-665E61A4863B

P1476

Q30492977-84C3B7C5-EF27-4469-8BD6-4F7D3F43EDEC

P2093

Q30492977-0CBD2306-4E75-4B7B-97C7-ACF5E5CF52C8

Q30492977-1552C94D-2AAF-4661-BC69-B29CE3A9A2AF

Q30492977-1C945EF6-170D-414D-93C0-F13B56BCD85D

Q30492977-21A91C93-100E-4A34-AB42-315FD20A7F52

Q30492977-22E0A8BA-111B-4267-8137-001EA0036AF0

Q30492977-274874C1-510D-4E36-B60C-8C8E798A9A5D

Q30492977-346CC8AD-EAAB-4CD3-B84E-FC42E17C43F2

Q30492977-3B36BF55-0E68-4801-941D-7E0E2B64C989

Q30492977-46F3760A-5BDB-4872-83F6-97A59BEF5F5E

Q30492977-5047B3B9-C6C1-4EA2-B623-5FE61E64F09D

P2860

Q30492977-14641D37-C44C-4AAF-8D2C-4D7DB1C795D3

Q30492977-1A329B78-4F41-40D5-9C73-43BE9CBBCF9E

Q30492977-3A1FD931-3F61-4194-BF2C-87B2C96B5901

Q30492977-3D1EE463-03B4-46C5-91BC-8ED59EECEA04

Q30492977-3DB50468-22F8-4876-8942-0CA731726173

Q30492977-4DB383D8-0402-4323-94EF-6B158BBDA377

Q30492977-52E25BBC-25B1-4A50-A074-B6BB8B96CB71

Q30492977-740A1C8E-432C-46BB-9AF5-905BCEBBC0AD

Q30492977-7CE79E2D-C089-45E6-BD82-B3C66B84AE63

Q30492977-80EE8CD9-7323-4BB0-9AC5-B421043DF29A

P304

Q30492977-32C31B4F-E9E0-4042-9087-CA611336E892

P31

Q30492977-0DA64548-29BB-4E3A-992C-3B597E691513

P356

Q30492977-BA9CB7AF-B613-4844-93F9-876DF88741B5

P407

Q30492977-51BEC5A6-82B9-47D9-B237-5DC2842F08A1

P433

Q30492977-9F3285D6-4BD9-43C9-8F1C-E3A2F700CFD2

P478

Q30492977-4B618AB7-E180-4CCA-A745-3D840235952C

P50

Q30492977-00A2912D-36A9-4B5E-A911-FCB70231A548

Q30492977-39E18421-B2A5-4C94-B114-936DA08A6598

Q30492977-483ABBBF-78CB-4B54-9AFB-0064C0D6AA8C

Q30492977-6915AE84-E1DD-444A-9338-92C84DADB144

Q30492977-7A478FAE-DDA7-4638-A4C3-E9DDFEFE7F99

Q30492977-8D8DF10C-8514-415D-A77A-CD467391B98C

Q30492977-C1DDDB5A-5464-4B68-AA7A-9B539274773A

Q30492977-C41AF789-F7B5-466B-8BD3-C37DF94116C4

Q30492977-C54759F5-0E62-4849-B1BE-83967290B52F

Q30492977-DDA9F358-F3F1-4BE4-86FB-239EC21B416C

P577

Q30492977-0408631A-7BA5-4732-B1E9-C87AB473BF78

P5875

Q30492977-CAFB5257-8DF8-4008-A4AC-5855DC1B5F4B

P698

Q30492977-75E6B867-D04C-4EFD-BE9B-D494B77D9876

P932

Q30492977-CB0B3B3D-4BFE-4CD8-B77E-775288A09B8D

P356

P1433

Journal of the National Cancer Institute

P1476

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

@en

P2093

Albert Tenesa

http://www.w3.org/2001/XMLSchema#string

Anja Wagner

http://www.w3.org/2001/XMLSchema#string

Annette H J T Vriends

http://www.w3.org/2001/XMLSchema#string

Barbara Leggett

http://www.w3.org/2001/XMLSchema#string

Darren M White

http://www.w3.org/2001/XMLSchema#string

Dutch Lynch Syndrome Study Group

http://www.w3.org/2001/XMLSchema#string

Encarna B Gomez Garcia

http://www.w3.org/2001/XMLSchema#string

Finlay Macrae

http://www.w3.org/2001/XMLSchema#string

Graeme Suthers

http://www.w3.org/2001/XMLSchema#string

Heather Hampel

http://www.w3.org/2001/XMLSchema#string

P2860

The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations

Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term.

Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree

Evidence for autosomal dominant inheritance of prostate cancer.

Cancer risk in mutation carriers of DNA-mismatch-repair genes.

Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment

Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians.

P304

193-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJP473

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Graham G. Giles

Malcolm G. Dunlop

Daniel D Buchanan

Jenny N. Poynter

Albert de la Chapelle

P577

2009-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40759495

http://www.w3.org/2001/XMLSchema#string

P698

20028993

http://www.w3.org/2001/XMLSchema#string

P932

2815724

http://www.w3.org/2001/XMLSchema#string